Intratumoral TriMix Injections in Early Breast Cancer Patients (TMBA)

• ClinicalTrials.gov Identifier: NCT03788083
• Recruitment Status: Recruiting
• First Posted: December 27, 2018
• Last Update Posted: May 19, 2022
• Sponsor: Universitair Ziekenhuis Brussel
• Collaborator: eTheRNA immunotherapies
• Information provided by (Responsible Party): Universitair Ziekenhuis Brussel

Study Description

Brief Summary:

Patients with early breast cancer and accessible tumor lesions (1.00 to 10 ml volume) that are eligible to either surgical removal of their tumor or neoadjuvant chemotherapy will be injected with the IMP. Patients will be either treated with placebo (buffer alone, 12 patients) or with TriMix mRNA at three dose levels [8 at dose level I (1mg/ml), 8 at dose level II (3mg/ml), and 8 at dose level III (6mg/ml). The volume injected in this group will be adjusted to the tumour volume to ensure a perfusion of around 33% of the tumour volume (33% +/- 5%). Therefore, depending on the patients' tumour size, 500, 1000 or 2000 µl of TriMix mRNA solution or placebo solution will be injected into each tumor. Each patient will receive three administrations of TriMix prior to start of general treatment (surgery or neoadjuvant chemotherapy) separated by one week (7 days +/- 2 days) interval. The last administration will be performed 2 days preoperatively or start of neoadjuvant chemotherapy.

The tumor and peripheral blood samples will be analyzed for immunological changes. If it is decided by the multidisciplinary team that neoadjuvant therapy is more appropriate for the patient, a second tumor biopsy (instead of surgical resection) will be taken 2 days after third administration of TriMix mRNA to assess immunological changes within the tumor. Similarly, patients that refuses to undergo surgery or to receive neoadjuvant chemotherapy can be enrolled into the trial, if they accept three administrations of TriMix followed by a second tumor biopsy.

The study will start with recruitment of the placebo group. The enrollment of the first three patients in each cohort with Trimix mRNA will be staggered with at least one day between the first dose of each individual patient. One week after the third patient of a cohort received the third TriMix mRNA administration, an overall evaluation of the safety and tolerability of this cohort will be done by the principal investigator. The results will be reviewed by an in-house dose evaluation committee overseeing the safety and tolerability of TriMix mRNA.

Condition or disease	Intervention/treatment	Phase
Breast Cancer Female; Early-stage Breast Cancer	Drug: Trimix; Drug: Placebo	Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 36 participants
• Allocation: Non-Randomized
• Intervention Model: Sequential Assignment
• Masking: Single (Participant)
• Masking Description: Subjects will not know whether an active or non-active substance is being injected. The choice for TriMix or placebo will take place according to the predefined schedule and can not be influenced by the patient or the investigator. Only after the comparison of the tumour tissue before (the initial biopsy where the diagnosis was made) and after (obtained at second biopsy or surgery) the intratumoral injection, it will be known whether mRNA or non-active product was used for the injection.
• Primary Purpose: Treatment
• Official Title: A Phase I Study on the Safety and Immune-modulatory Effect of Intratumoral (i.t.) Administration of mRNA (Messenger RNA) Encoding Dendritic Cell Activating Proteins in Patients With Early, Resectable Breast Cancer
• Actual Study Start Date: November 12, 2018
• Estimated Primary Completion Date: September 30, 2024
• Estimated Study Completion Date: December 30, 2024

Arms and Interventions

Arm	Intervention/treatment
Placebo Comparator: placebo	Drug: Placebo; Intratumoral placebo injection
Active Comparator: TriMix	Drug: Trimix; Intratumoral TriMix injection

Outcome Measures

Primary Outcome Measures :

1. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 [ Time Frame: 2 years ]
   Number of patients with adverse events, total number of adverse events, dose limiting toxicities

Secondary Outcome Measures :

1. Tumor microenvironment changes induced by intratumoral TriMix mRNA [ Time Frame: 30 days ]
   Tumor microenvironment changes induced by intratumoral TriMix mRNA administration from diagnostic biopsy to day 21 (visit 5) assessed by immunohistochemistry.
2. Tumor microenvironment changes induced by intratumoral TriMix mRNA [ Time Frame: 30 days ]
   Tumor microenvironment changes induced by intratumoral TriMix mRNA administration from diagnostic biopsy to day 21 (visit 5) assessed by nanoString gene profiling
3. TriMix mRNA induced T-cell responses [ Time Frame: 30 days ]
   TriMix mRNA induced T-cell responses assessed by immunoassays in situ and in peripheral blood

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 85 Years (Adult, Older Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Age greater than or equal to 18 years and less than or equal to 85 yrs
2. Histologically proven breast cancer eligible for curative surgery (with or without the need for neoadjuvant chemotherapy) with one or more injection-accessible (allowing ultrasound guidance) nodal tumors.
3. Injectable tumor lesions must have a volume between 1.00 and 10 ml, only one lesion per patient will be injected
4. ECOG performance status of 0 or 1
5. Willing to give informed consent in writing
6. Willing and able to attend the scheduled study visits and to comply with the study procedures
7. No prior therapy for ipsilateral breast cancer
8. Normal lab parameters: white cell count ≥ 3,000/mm3, hemoglobin ≥ 10mg/dl, platelet count ≥ 100,000/mm3, serum creatinine ≤ 1.5 x institutional ULN, bilirubin ≤ 2.0 mg/dl aspartate aminotransferase/alanine aminotransferase/ alkaline phosphatase ≤ 2 x the upper normal limit (AST< 72 U/l, ALT < 104 U/l, AP < 252 U/l)
9. Adequate Coagulation Parameters with: Prothrombin INR < 1.5; Partial Thromboplastin Time < 1.5 x 34.4 sec (51.6 sec)

10. Female patients of childbearing potential should have a negative serum pregnancy test at screening visit and should use a highly efficient method of birth control for the duration of treatment and until the first menses after a 4 week period after the last dose of study medication. Highly effective birth control methods include:

    • combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation administered oral, intravaginal or transdermal.
    • progestogen-only hormonal contraception associated with inhibition of ovulation administered oral, as an injectable or implantable formulation.
    • intrauterine device
    • intrauterine hormone-releasing system
    • bilateral tubal occlusion
    • vasectomised partner
    • abstinence from sexual intercourse

Exclusion Criteria:

1. Male patients
2. Patients with stage III-IV breast cancer (AJCC 8th edition)
3. Patients with highly vascularized tumor or important post-biopsy hematoma
4. Previous chemotherapy for breast cancer or other types of cancer within the last five years
5. Other malignancies other than non-melanoma skin cancer, or controlled superficial bladder cancer. In the event of prior malignancies treated surgically, the patient must be considered NED (no evidence of disease) for a minimum of 3 years prior to enrolment
6. Patients with a history of autoimmune disease (inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, rheumatoid arthritis or multiple sclerosis) other auto-immune or debilitating diseases. Vitiligo is not an exclusion criterion.
7. Patients with serious intercurrent chronic or acute illness such as pulmonary [asthma or chronic obstructive pulmonary disease (COPD)] or cardiac (NYHA class III or IV) or hepatic disease or other illness considered by the P.I. to constitute an unwarranted high risk for investigational drug treatment
8. Patients with significant psychiatric disabilities or seizure disorders
9. Legal incapacity or limited legal capacity
10. Patients on steroid therapy > 10 mg prednisone (or equivalent) or other immunosuppressive agents such as azathioprine or cyclosporine A are excluded on the basis of potential immune suppression. Patients must have had 8 weeks of discontinuation of any steroid therapy exceeding > 10 mg prednisone (or equivalent) prior to enrolment
11. Presence of an active acute or chronic infection, including symptomatic urinary tract infection, HIV (as determined by ELISA and confirmed by Western Blot) or viral hepatitis (as determined by HBsAg and Hepatitis C serology)
12. Patient is pregnant or is currently breast-feeding

Contacts and Locations

Contacts

Contact: UZ Brussel; +32 2 477 6015; borstkliniek@uzbrussel.be

Locations

Belgium

UZ Brussel; Recruiting

Jette, Brussel, Belgium, 1090

Contact: UZ Brussel +32 2 477 6015 borstkliniek@uzbrussel.be

Principal Investigator: Marian Vanhoeij, MD

Sponsors and Collaborators

Universitair Ziekenhuis Brussel

eTheRNA immunotherapies

Investigators

• Principal Investigator: Marian Vanhoeij, MD; Universitair Ziekenhuis Brussel

More Information

• Responsible Party: Universitair Ziekenhuis Brussel
• ClinicalTrials.gov Identifier: NCT03788083
• Other Study ID Numbers: TriMix-Breast
• First Posted: December 27, 2018
• Last Update Posted: May 19, 2022
• Last Verified: May 2022

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Universitair Ziekenhuis Brussel:

immune therapy; dendritic cells; immune priming

Additional relevant MeSH terms:

Breast Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases